Curcumin's Effect on Inflammatory Response following Percutaneous Coronary Intervention in Adult Patients with Stable Coronary Heart Disease

Abstract

Cardiovascular diseases play major roles in the health problems worldwide especially in Indonesia. Percutaneous coronary intervention (PCI) is a minimally invasive procedure with relatively low complications. However, high inflammatory response post-PCI has showed adverse events even after administration of standard medication. Previous studies showed that curcumin was able to reduce inflammatory response in adult patients with stable coronary heart disease (CHD). This article determines the efficacy of oral administration of curcumin in reducing inflammatory response post-PCI with stable CHD. A double-blind randomized controlled trial on 50 adult patients comparing curcumin and placebo was performed in Cipto Mangunkusumo General Hospital and Jakarta Heart Center within April and June 2015. Either curcumin (45 mg/day) or placebo was given 7 days prior to PCI until 2 days after PCI. Inflammatory markers (high-sensitivity C-reactive protein [hsCRP] and soluble CD40 ligand [sCD40L]) were measured in three phases (7 days prior PCI, 24 hours post-PCI, and 48 hours post-PCI). There were no significant differences in the reduction of hsCRP and sCD40L between curcumin and placebo groups in three phases of measurement. Curcumin significantly reduce the serum hsCRP (p = 0.006) and sCD40L (p = 0.002) 7 days before PCI to 48 hours post-PCI. The decrement of hsCRP (−14.2% vs. –7.4%) and sCD40L (−24.3% vs. –13.2%) from 24 to 48 hours post-PCI was higher in the curcumin group than placebo group. The administration of curcumin 45 mg dose daily for 7 days prior PCI until 48 hours post-PCI is useful in reducing inflammatory response post-PCI with stable CHD.

Keywords

curcumin - inflammatory response - PCI - stable CHD

• References

• 1 Estimates GH. Deaths, Disability-Adjusted Life Year (DALYs), Years of Life Lost (YLL) and Years Lost due to Disability (YLD) by Cause, Age and Sex, 2000–2012. Geneva: World Health Organization; 2012
• 2 Ministry of Health Republic of Indonesia. Basic Health Research. Jakarta: 2013. https://www.kemkes.go.id/resources/download/general/Hasil%20Riskesdas%202013.pdf
• 3 Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1 (8058): 263
• 4 Means G, End C, Kaul P. Management of percutaneous coronary intervention complications. Curr Treat Options Cardiovasc Med 2017; 19 (04) 25
• 5 Kalkman DN, Aquino M, Claessen BE. et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J 2018; 39 (46) 4101-4108
• 6 Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253 (5024): 1129-1132
• 7 Holmes Jr DR, Vlietstra RE, Smith HC. et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53 (12) 77C-81C
• 8 Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124 (23) e574-e651
• 9 Nobuyoshi M, Kimura T, Nosaka H. et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12 (03) 616-623
• 10 Serruys PW, Luijten HE, Beatt KJ. et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77 (02) 361-371
• 11 Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys 2012; 49 (05) 306-315
• 12 Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: a pilot randomized, double-blind, placebo-controlled trial. Iran J Pharm Res 2015; 14 (02) 479-486
• 13 Alwi I. Hubungan faktor metabolik dengan respons infllamasi pada sindrom koroner akut pasien diabetes mellitus tipe 2. Universitas Indonesia; 2006
• 14 Cheng ALHC, Hsu CH, Lin JK. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21 (4B): 2895-2900
• 15 Lao CD, Ruffin IV MT, Normolle D. et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10
• 16 Sharma RA, McLelland HR, Hill KA. et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7 (07) 1894-1900
• 17 Tsimikas S, Lau HK, Han KR. et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004; 109 (25) 3164-3170
• 18 Kim TH, Jiang HH, Youn YS. et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011; 403 (1-2): 285-291
• 19 Li TT, Xie Y, Guo Y. et al. Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: an intravascular ultrasound study. Chin Med J (Engl) 2011; 124 (12) 1840-1847
• 20 DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 2012; 11: 79